Greenland Mines Ltd GRML
Biotechnology: Biological Products (No Diagnostic Substances) · IPO 2022 · data as of November 13, 2026
Greenland Mines Ltd (GRML) is a healthcare company listed in the US with a market value of about $49M.
Its overall Stock Analiz score is 0.8 out of 5 (weak). The strongest part is financial health (4/5); the weakest is value (0/5).
Key numbers: a 5-year average ROIC of -141%.
About Greenland Mines
Greenland Mines is listed in the US and classified in biotechnology: biological products (no diagnostic substances), IPO year 2022. It was profitable in 1 of the last 4 years in our data.
Score: 0.8 / 5
Checks passed
- More cash than debt, or low debt to equity
- Interest covered more than 5 times
- Debt below 3 years of free cash flow
- Liabilities below 60% of assets
Checks not passed
- P/E below 25
- P/E below the industry median
- P/FCF below 20
- Price below intrinsic value (DCF, moderate assumptions)
- PEG below 1.5
- Revenue growth above 10% last year
- 3-year revenue growth above 10% a year
- Profit margin improving
Valuation
Growth and quality
Financials, last 4 years
| Fiscal year | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|
| Revenue | — | — | — | — |
| Net income | -$11M | -$6M | -$707458 | $1M |
| Free cash flow | — | — | — | — |
| EPS (diluted) | $-0.22 | $-0.32 | $-0.05 | — |
| Net margin | — | — | — | — |
| ROIC | -59.7% | -306.9% | -57.6% | — |
From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.
What analysts expect
The average 12-month price target from 1 analysts is $110.00, 2947% above the current price; targets range from $110.00 to $110.00; the consensus rating is “none”.
Frequently asked questions
Does Greenland Mines pay a dividend?
Not currently.
Is Greenland Mines a good stock to buy?
We do not give buy or sell advice. Greenland Mines scores 0.8 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.
Similar companies
Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.